“Iron free” zinc oxide nanoparticles with ion-leaking properties disrupt intracellular ROS and iron homeostasis to induce ferroptosis

Changping Zhang1, Zixuan Liu2, Yuhao Zhang1, Liang Ma1, Erqun Song2 and Yang Song2

Abstract
Exposure to nanomaterials (NMs) is an emerging threat to human health, and the understanding of their intracellular behavior and related toxic effects is urgently needed. Ferroptosis is a newly discovered, iron-mediated cell death that is distinctive from apoptosis or other cell-death pathways. No evidence currently exists for the effect of “iron free” engineered NMs on ferroptosis. We showed by several approaches that (1) zinc oxide nanoparticles (ZnO NPs)-induced cell death involves ferroptosis; (2) ZnO NPs-triggered ferroptosis is associated with elevation of reactive oxygen species (ROS) and lipid peroxidation, along with depletion of glutathione (GSH) and downregulation of glutathione peroxidase 4 (GPx4); (3) ZnO NPs disrupt intracellular iron homeostasis by orchestrating iron uptake, storage and export; (4) p53 largely participates in ZnO NPs-induced ferroptosis; and (5) ZnO particle remnants and dissolved zinc ion both contribute to ferroptosis. In conclusion, our data provide a new mechanistic rationale for ferroptosis as a novel cell-death phenotype induced by engineered NMs.

Introduction
Nanomaterials (NMs) readily enter the human body through respiratory inhalation, oral ingestion or a dermal route, cross the plasma membrane and reach the inside of cells, ultimately triggering cell death1. The disruption of cell-death homeostasis is associated with various diseases, including neurodegenerative diseases, immune disorders, diabetes and cancers. Thereafter, it is important to elaborate the molecular processes of NMs-regulated cell death2,3. Among them, the majority of cell-death modalities are associated with NMs-induced cytotoxicities.

Ferroptosis is a recently recognized cell death with unique morphological, genetic and biochemical characteristics that are distinct from apoptosis, autophagy or necrosis5,5. Ferroptosis is an iron-dependent accumulation of lipid reactive oxygen species (ROS) process. Small molecule inducers or inhibitors of ferroptosis through targeting iron metabolism or lipid peroxidation have been extensively studied6.

Advances in nanotechnology have stimulated the enthusiasm in the designing of multifunctional NMs for cancerous therapeutic applications through ferroptotic mechanisms7. However, most of the studies used iron or iron-oxide-based NMs8–10. Nevertheless, in addition to biomedical applications, human beings are unconsciously exposed to numerous of engineered NMs through consumer products. To this end, from a safety perspective, we ought to assess whether ferroptosis occurs upon “iron free” engineered NMs exposure and decipher the corresponding mechanism(s).

ZnO nanoparticles (ZnO NPs) are often used in food additives for nutritional purposes, sunscreen cream for absorbance of UV light, and antimicrobial agents for skin protection. In addition, ZnO NPs have been applied to many medical applications, such as drug delivery, tissue
Materials and methods

Chemical and reagents

Cell Counting Kit-8 (CCK8) assay kit was purchased from Bimake Inc. (USA). 2′,7′-dichlorofluorescein diacetate (DCFH-DA) was purchased from Sigma-Aldrich Inc. (Sigma, USA). MitoTracker® Deep Red FM, Lyso Tracker Red, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI), JC-1 staining kit and propidium iodide (PI) were purchased from YE SEN Inc. (Shanghai, China). N-(6-chloro-1-pyridin-3-yl)-N′-toluenesulphonamide (TSQ) was purchased from AAT BIOQUEST (USA). Annexin V-FITC/PI, lactate dehydrogenase (LDH), the cleaved caspase 8 and caspase 3 polyclonal primary antibodies from Wanleibio (Nanjing, China). Acridine orange-ethidium bromide (AO-EB) double stain kit and Lillie divalent iron staining solution were supplied by Solarbio Inc. (Beijing, China). Ferrostatin-1 (FTH), iron importers transferrin receptor protein 1 (TFRC), SLC7A11, and GPx4 polyclonal primary antibodies were purchased from Target Mol (Boston, USA). The mouse p53, ferritin heteropolymers ferritin light chain (FTL) and ferritin heavy chain (FTH), iron importers transferrin receptor protein 1 (TFRC), SLC7A11, and GPx4 polyclonal primary antibodies were purchased from Santa Cruz Biotechnology (USA). The mouse SAT1 and DMT1 polyclonal primary antibodies were purchased from Bios (Beijing, China). β-Actin polyclonal primary antibody, goat-anti-rabbit IgG-HRP conjugated secondary antibody, and goat-anti-mouse IgG-HRP conjugated secondary antibody were supplied by Sangon Biotech Co., Ltd. (Shanghai, China). ZnO NPs (>99.9% purity) and ZnCl₂ standard solution (0.1 M) were purchased from Aladdin Reagent Database Inc. (Shanghai, China).

Fluorescent labeling of ZnO NPs

Briefly, 20 mg ZnO NPs were dispersed in 15 mL absolute ethanol. A solution of 30 μL APTES diluted in 1 mL absolute ethanol was added to the particle suspensions, sonicated and stirred under nitrogen atmosphere at room temperature for 20 h. The modified NPs were collected by centrifuging and removing the supernatant. After washing, the modified NPs were resuspended in 15 mL absolute ethanol and mixed with a solution contain 1 mg FITC and 0.5 mL absolute ethanol. The suspension was stirred for 4 h and fluorescein isothiocyanate (FITC)-labeled (F-ZnO) NPs were collected by centrifugation. After thorough washing of the labeled materials with absolute ethanol, the particles were dried under vacuum to remove the organic solvent and stored as dry powders. The maximum absorption peak of synthesized F-ZnO NPs is 539 nm.

Characterization of ZnO and F-ZnO NPs

ZnO NPs and F-ZnO NPs were characterized by TEM (JEM1200EX, Japan). The sample was diluted with water, dropped on a carbon film copper mesh, and the sample was dried and stained with uranyl acetate, and naturally dried in a fume hood. The dried sample was placed in an observation room with an accelerating voltage of 120 kV and photographed. The crystalline nature of ZnO NPs was carried out by XRD (BRUCKER D8, Germany). Place the sample into the sample stage and compact it into a flat surface. The tube current is 40 mA, the tube voltage is 40 kV, the Cu target wavelength is 1.5406 Å, and the Co target wavelength is 1.75926 Å. The X-ray patterns were matched literature. Hydrodynamic diameter, PDI and zeta potential of ZnO and F-ZnO NPs were determined using a Mastersizer Micro (Malvern, UK) in pure water and RPMI1640 medium. ZnO NPs and F-ZnO NPs were dispersed in water at a concentration of 15 μg/mL, respectively. Then, the suspensions were sonicated using a sonicator bath at room temperature for 10 min at 80 W.

Cell culture

HUVECs, LO2, and RAW264.7 obtained from the American Type Culture Collection (ATCC, USA), cultured in complete RPMI1640 medium containing 10% fetal bovine serum (FBS). MDA-MB231, Hepa 1-6, and Hela obtained from the American Type Culture Collection (ATCC, USA), cultured in complete DMEM medium containing 10% fetal bovine serum (FBS). PC12, obtained from the American Type Culture Collection (ATCC, USA), was cultured in complete RPMI1640 medium containing 10% newborn calf serum (NCS). MDA-MB-453 was cultured in complete L15 medium containing 10% NCS. BT-474, obtained from cell bank of the Chinese Academy of Sciences, was cultured in complete RPMI1640 medium containing 15% FBS. Cells were incubated at 37 °C in a humidified atmosphere of 5% CO₂ in air.

Cell viability assay

Cell viability was determined by CCK8 assay. HUVECs (5 × 10³/well) were seeded in a 96-well plate overnight before treatment with ZnO NPs for 24 h with or without other
co-treatment. Subsequently, 100 μL of CCK8 solution (10%) was added to each well and incubated at 37 °C for 2 h. The absorbance of each culture well was measured with a microplate reader (BioTek, USA) at a wavelength of 450 nm.

**LDH release assay**

Briefly, cells were cultured in 24-well plates with ~8 × 10^4 cells per well. After 12 h of growth, cells were then treated with ZnO NPs at concentrations of 0, 5, 10, and 15 μg/mL for 24 h. The supernatants were collected, 100 μL cell medium was used for LDH activity analysis, the absorbance at 450 nm was measured by microplate reader (BioTek ELX800, USA). The amount of LDH released is expressed as LDH activity (U/L) in culture media.

**Annexin V-FITC/PI staining analysis**

Annexin V-FITC/PI staining was performed on a BD FACS Melody™ flow cytometry. After 24 h of growth, cells were treated by ZnO NPs at concentrations of 0, 5, 10, and 15 μg/mL for 24 h. In each group, at least 1 × 10^4 cells were analyzed to determine the percentage of apoptotic cells. The results are presented as percentage of apoptotic cells (including early and late apoptotic cells).

**PI staining analysis**

Approximately 1 × 10^6 cells/well were seeded in 6-well plates overnight followed by the treatment of ZnO NPs for 24 h. Corresponding inhibitors or activators were introduced 1 h prior to ZnO NPs (10 μg/mL) treatment. Cells were incubated with PI staining in the dark at 37 °C for 15 min. Cells were washed twice with PBS. The cellular fluorescence was analyzed by a BD FACS Melody™ flow cytometry. A total of 1 × 10^4 event was acquired for each sample from three independent experiments.

**AO-EB double staining**

Cells were cultured in confocal cell culture dish with ~8 × 10^4 cells per well. After 24 h of growth, cells were treated by ZnO NPs at concentrations of 0, 5, 10, and 15 μg/mL for 24 h. Then, cells were incubated with AO-EB staining in the dark at 37 °C for 30 min. After the stained cells were rinsed three times with PBS, the cells were examined under a reversed fluorescence microscope (Olympus IX71).

**Mitochondrial membrane potential (ΔΨm, MMP) assay**

Cells were cultured in confocal cell culture dish with ~8 × 10^4 cells per well. After 24 h of growth, cells were treated by ZnO NPs at concentrations of 0, 5, 10, and 15 μg/mL for 24 h. The changes in ΔΨm were monitored after staining with JC-1 (1 μg/mL) probe. Analysis was performed on a BD FACS Melody™ flow cytometry.

**Mitochondrial morphology analysis**

Cells were cultured in confocal cell culture dish, with ~8 × 10^4 cells per well. After 24 h of growth, cells were treated by ZnO NPs at concentrations of 10 μg/mL for additional 24 h. Erastin (25 μM) was used as a positive control. Cells were washed twice with PBS, then, cells were incubated with Mito Tracker® Deep Red FM in the dark at 37 °C for 30 min. After the stained cells were rinsed three times with PBS, cells were imaged under confocal microscope (Nikon N-SIM).

**TEM analysis of cells**

TEM analysis was performed to observe the morphology and microstructure of ZnO NPs-treated HUVECs. Briefly, HUVECs were treated with ZnO NPs (10 μg/mL) or erastin (25 μM) for 24 h. Before cells collection, cells were washed twice with PBS and fixed in 4% glutaraldehyde at room temperature for 1 h followed by 4 °C for additional 12 h. Next, cells were post-fixed with 1% OsO4 and embedded in epon. Then, ultrathin sections were stained with uranyl acetate/lead citrate and visualized in a Hitachi-7500 TEM instrument (Hitachi, Tokyo, Japan).

**Lillie divalent iron staining**

Cells were cultured in confocal cell culture dish, with ~8 × 10^4 cells per well. After 24 h of growth, cells were treated by NPs or ZnCl2 for additional 24 h. After washed twice with PBS, cells were incubated with Lillie divalent iron staining reagent in the dark at 37 °C for 1 h. After rinsed three times with PBS, the cells were examined under a reversed fluorescence microscope (Olympus IX71).

**ROS level measurement**

Approximately 1 × 10^6 cells/well were seeded in 6-well plates overnight followed by the treatment of ZnO NPs for 24 h. Corresponding inhibitors or activators were introduced 1 h prior to ZnO NPs treatment. Cells were incubated with DCFH-DA indicator in the dark at 37 °C for 1 h. After rinsed three times with PBS, the cells were examined under a reversed fluorescence microscope (Olympus IX71).

**GSH level measurement**

HUVECs at a concentration of 2 × 10^5 cells/well were seeded in 6-well plates. Cells were treated with ZnO NPs (0, 5, and 10 μg/mL) for 24 h. Cells were harvested and cell number were determined. Total GSH was measured by a commercial GSH kit according to the manufacturer’s instructions.
MDA level measurement
HUVECs at a concentration of 2 × 10^5 cells/well were seeded in 6-well plates. Cells were treated with ZnO NPs (0, 5, and 10 μg/mL) for 24 h. Cells were harvested and cell numbers were determined. MDA level was measured by a commercial MDA kit according to the manufacturer’s instructions.

siRNA interference
HUVECs were transfected with 25 nM siRNA for P53, SAT1, ACSL4, ALOX15 or scrambled siRNA using siRNA-mate transfection reagent according to the manufacturer's protocol. The sense-strand sequences of siRNA duplexes were listed in Supplementary Table 3.

Western blotting assay
HUVECs at a concentration of 2 × 10^5 cells/well were seeded in 6-well plates. Cells were treated with ZnO NPs (0, 5, and 10 μg/mL) for 24 h. After harvest, the protein concentrations were detected by the BCA protein assay according to the manufacturer’s instruction. Thirty micrograms of cellular protein from each group was blotted onto PVDF membrane following separation on 12.5% SDS-PAGE. The immuno-blot was incubated with the blocking solution (8% skim milk) at room temperature for 2 h, followed by incubation with a corresponding primary antibody at 37 °C for 3 h. After washing with Tween 20/Tris-buffered saline (TBST), the immune-blot was incubated with respective secondary antibody (1:5000) for 2 h at room temperature. Followed by visualization using the ECL system. Representative images were chosen from at least three independent experiments. Protein expression levels were standardized by β-actin in different cell substrates.

RNA extraction and real-time quantitative PCR (RT-qPCR)
Total RNA was extracted with a total RNA purification kit (BioTeke, Beijing, China) as described in the manufacturer’s instructions. The purified RNA (2 μg) was reverse transcribed into cDNA with the transcription first strand cDNA synthesis kit (Roche, Switzerland). Then, cDNA was used to perform RT-qPCR analysis using the Light Cycler 96 instrument protocol with FastStart Essential DNA Green Master (Roche, Switzerland). Subsequently, 35 cycles of PCR were carried out with denaturation at 94 °C for 20 s, annealing at the most suitable temperature for 30 s and extension at 72 °C for 30 s, followed by a final incubation at 72 °C for 10 min. The primers used for the amplification were listed in Supplementary Table 4.

Atomic absorption spectroscopy (AAS) assay
HUVECs were seeded in 10 cm plates and exposed to ZnO NPs or ZnCl2 dispersions for 24 h. Then, cells were thoroughly washed, harvested, and counted. The supernatant and total Zn^{2+} concentration in solution was determined using AAS in the graphite furnace mode (TAS-990, Persee, China). For dissociated Zn^{2+} concentration measurement, the cell lysate was centrifuged at 30,000 × g for 1 h and supernatant was collected. For total Zn^{2+} concentration measurement, the cell lysate was acidified to pH < 2 with 65% HNO3 followed by digestion (1 mL sample + 1 mL 30 wt% H2O2, 3 mL 65 wt% HNO3 via water bath 75 °C for 6 h). Each experiment was performed in triplicate.

Zn^{2+} release in PBS and ALF
The Zn^{2+} release was also measured in PBS or ALF (artificial lysosomal fluid). The PBS (pH of 7.4) was used to mimic the physiological environment. The ALF (pH of 4.5) was intended to mimic the lysosomal acidic environment. ALF composition is according to previous publication. ZnO NPs dispersions were prepared in PBS or ALF and kept at 37 °C. After 24 h samples were centrifuged for 1 h at 15,000 × g, 4 °C, the supernatant was collected and analyzed by AAS.

Intracellular zinc imaging
HUVECs were pretreated in a culture medium containing 10 μg/mL of F-ZnO NPs for 24 h. After permeabilization and fixation, cells were then rinsed three times with PBS and stained in a PBS solution contains cellular membrane marker Dil (20 μM) or Zn^{2+}-specific fluorescent dye TSQ (30 μM) for 30 min. The cells were examined under a super-resolution confocal microscope (Nikon N-SIM) with an excitation wavelength of 405 nm. The average fluorescence intensity was quantitatively measured to reflect the intracellular Zn^{2+} concentration in HUVECs. The lysosomes were stained by 1 μM Lyso Tracker Red (YE SEN, China) and visualized with an excitation wavelength of 635 nm for the determination of subcellular location of ZnO NPs. F-ZnO NPs was visualized at an excitation wavelength of 488 nm.

Statistical analysis
All statistical analyses were evaluated by a one-way ANOVA and followed by a Tukey’s multiple-comparisons test. P < 0.05 was considered statistically significant. All the dates were expressed as mean ± standard deviations (S.D.).

Results
Characterization of ZnO and fluorescein isothiocyanate (FITC)-labeled (F-ZnO) NPs
The morphology and average size of ZnO NPs were determined by transmission electron microscopy (TEM). ZnO NPs have a near-spherical shape with an average primary diameter of 30 ± 10 nm (Supplementary Fig. 1).
ZnO NPs characterized by X-ray diffraction (XRD) with CuKα radiation revealed a crystalline nature structure which is consistent with the standard zincite, JCPDS 5-0664 (Supplementary Fig. 2). The hydrodynamic sizes and zeta potentials of ZnO and F-ZnO NPs were measured in ultrapure water and RPMI1640 medium after incubation at 37 °C (Supplementary Table 1). Both ZnO and F-ZnO NPs have a relatively uniform size with a low polydispersity index (PDI).

Cytotoxicity of ZnO NPs on human umbilical vein endothelial cells (HUVECs)

Epidemiologic and experimental studies have both demonstrated a correlation between NMs exposure and an increased incidence of cardiovascular diseases\(^{13,14}\). The current study was mainly conducted in HUVECs due to their cardiovascular relevance. ZnO NPs caused obvious decreases in cell viability (\(P < 0.01\) in the 10 \(\mu\)g/mL group and \(P < 0.001\) in the 15 \(\mu\)g/mL group) (Supplementary Fig. 3). A dose-dependent increase in LDH release after ZnO NPs treatment suggested ZnO NPs-induced cell death (Supplementary Fig. 4). Then, annexin V-FITC/propidium iodide (PI) staining results revealed a dose-dependent increase in annexin V-FITC/PI-positive cells after ZnO NPs challenge (\(-39\%\) in the 15 \(\mu\)g/mL group) (Supplementary Fig. 5). An acridine orange-ethidium bromide (AO-EB) staining assay revealed reduced green fluorescence and an increased orange fluorescence, suggesting necrotic-like cell death (Supplementary Fig. 6). Moreover, mitochondrial damage after exposure to ZnO NPs further confirmed ZnO NPs-associated cytotoxicity in HUVECs (Supplementary Fig. 7). Consistently, we also observed the cleavage of caspase 8 and 3, which are hallmarks of apoptosis activation parthanatos (Supplementary Fig. 8). For the following experiments, the maximum concentration of ZnO NPs exposure was set as 10 \(\mu\)g/mL (except for Zn\(^{2+}\) concentration measurement) to maintain >80% viable cells.

ZnO NPs trigger oxidative stress-dependent, iron-mediated ferroptosis

ROS generation and antioxidant depletion are common in ZnO NPs-treated cells\(^{15}\). Our results established that ZnO NPs cause glutathione (GSH) (Fig. 1a) and glutathione peroxidase (GPx) depletion (Fig. 1b). Using the DFCCH-DA probe as an ROS indicator, the results showed that ZnO NPs increase ROS levels in a dose-dependent manner (Fig. 1c). Consistently, malondialdehyde (MDA) levels were dramatically increased (Fig. 1d). Together, these results indicated ROS elevation caused by ZnO NPs.

Previous studies have described that not only apoptosis, but also necrosis and autophagy were induced by ZnO NPs\(^{11,16,17}\). Here, we questioned the involvement of ferroptosis in ZnO NPs-mediated cell death. We observed that the addition of specific cell-death inhibitors decreased the relative PI fluorescence induced by ZnO NPs (10 \(\mu\)g/mL) (Supplementary Fig. 9). The rescue effects of various inhibitors are consistent with previous studies that showed ZnO NPs-induced apoptosis, necroptosis, and autophagy\(^{16,17}\). Ferroptosis has its distinctive characteristics\(^{6,18}\), we further evaluated whether ZnO NPs lead to lipid peroxidation by measuring GPx4 levels at the transcriptional and posttranscriptional levels. Indeed, ZnO NPs decreased GPx4 mRNA (Fig. 1e) and protein levels (Supplementary Fig. 10), respectively. Together, the inhibition of system Xc\(^{−}\) and promotion of lipid peroxidation are critical events of ZnO NPs exposure, implying the occurrence of ferroptosis. Acyl-CoA synthetase long-chain family member 4 (ACSL4) contributes to the accumulation of lipid intermediates during ferroptosis and the loss of ACSL4 gene resulted in ferroptosis resistance\(^{19}\). Alternatively, ferroptosis is promoted by lipooxygenase (LOX)-catalyzed lipid hydroperoxide generation\(^{20}\). Therefore, we analyzed ACSL4 and ALOX15 genes by qRT-PCR, and the results indicated upregulation of expression of both genes (Fig. 1f, g). Furthermore, silencing of ACSL4 and ALOX15 decreased ZnO NPs-induced elevation of DCF fluorescence intensity, indicated the inhibition of intracellular ROS (Supplementary Fig. 11). The upregulation of prostaglandin-endoperoxide synthase 2 (PTGS2) has recently been identified as a potential molecular marker of ferroptosis\(^{18}\). In accordance, PTGS2 was found to be remarkably upregulated when HUVECs were treated with ZnO NPs (Fig. 1h).

Next, we revealed whether ferrous iron was required for ZnO NPs’ action through the co-treatment of cells with the potent iron chelator desferrioxamine (DFO). ZnO NPs-increased ROS level was almost completely attenuated in the presence of DFO (Fig. 1i). The co-treatment of DFO prevented cell death and LDH release triggered by ZnO NPs (Fig. 1j, k). The occurrence of ferroptosis in HUVECs line was confirmed by erastin (Supplementary Fig. 12). The combination of these results provides solid evidence of the ZnO NPs-induced susceptibility of HUVECs to ferroptosis.

ZnO NPs exposure disrupts iron homeostasis

Since the iron chelator DFO rescues ZnO NPs-induced cell death, we further studied the effect of ZnO NPs on iron homeostasis. Cellular iron homeostasis is orchestrated perfectly through three processes, i.e., uptake, storage and export\(^{6}\). As shown, the mRNA levels of iron importers transferrin receptor protein 1 (TFRC) (mediates iron import) and divalent metal transporter 1 (DMT1) [facilitates Fe\(^{2+}\) transport to a labile iron pool (LIP) in the cytoplasm] were both significantly upregulated (Fig. 2a, b). Iron export is controlled solely by the iron efflux pump...
Ferroportin (FPN1)\textsuperscript{21}. In addition to increasing iron uptake, ZnO NPs increase intracellular iron by modulating the iron-export gene levels. Therefore, systemic iron homeostasis is governed by the hepcidin-ferroportin signaling axis. We discovered a noticeable increase in FPN1 at the transcriptional level by ZnO NPs (Fig. 2c). FPN1 can be regulated at the transcriptional, posttranscriptional and posttranslational levels\textsuperscript{22,23}. Hepcidin, an iron-regulatory hormone, posttranslationally regulates FPN1 through its binding and proteolysis of FPN1 in lysosomes\textsuperscript{24}. However, contradictory effects were obtained, e.g., increased Bach1 and MZF1 mRNA levels upon ZnO NPs exposure (Supplementary Fig. 13).

A direct measurement of free iron in the cellular compartment is necessary for reveal the effect of ZnO NPs on iron homeostasis. A commonly used calcein-AM assay for LIP measurement is not suitable in our study due to the effect of Zn\textsuperscript{2+} released by ZnO NPs. We thus investigated ferrous iron accumulation by Lillie ferrous iron staining assay. The obvious increases in deep blue foci in the ZnO NPs groups are evidence of an increase in ferrous iron (Fig. 2d). Consistently, the mRNA levels of FTH and FTL were significantly downregulated by ZnO NPs (Fig. 2e, f). Consistently, the iron inbound protein TFRC and DMT1 expressions were upregulated, and the iron outbound protein FTH and FTL expressions were downregulated (Supplementary Fig. 14).

Undoubtedly, these results suggested defects in mitochondrial iron transport and utilization that suggested mitochondrial iron overload\textsuperscript{25}.

ZnO NPs exposure dysregulates mitochondrial dynamics
Iron overload is usually accompanied by mitochondrial oxidative stress, leading to mitochondrial dysfunction\textsuperscript{26}.

---

**Fig. 1** ZnO NPs trigger oxidative stress-dependent, iron-mediated ferroptosis. HUVECs were treated with ZnO NPs (0, 5, and 10 \( \mu \)g/mL) for 24 h. a GSH, b GPx, c ROS, and d MDA levels were measured. Total RNA was extracted for the analysis of mRNA levels of interest using qRT-PCR. e GPx4, f ACSL4, g ALOX15, and h PTGS2 mRNA. HUVECs were pretreated with DFO (100 \( \mu \)M) for 1 h in the presence of 10 \( \mu \)g/mL ZnO NPs. i The generation of ROS was determined by the DCFH-DA probe, MFI: mean fluorescence intensity. j Cell viability analysis. k LDH leakage assay. Data are shown as the mean ± S.D. from three independent experiments.
The typical cell morphology of ferroptosis is smaller mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria cristae, as well as outer mitochondrial membrane rupture. Currently, ZnO NPs-treated cells showed shrunk mitochondria and fused mitochondrial cristae (Fig. 3a), which are reminiscent of ferroptotic cancer cells observed in response to erastin. One of the direct molecular targets of erastin is the mitochondrial voltage-dependent anion channel (VDAC) protein, which mediates mitochondrial iron uptake and enhances ferroptosis. Indeed, VDAC2 and VDAC3 expression was considerably upregulated with ZnO NPs (Fig. 3b, c). The ZnO NPs-treated group showed a large number of fragmented, smaller and short-tubular mitochondria that resemble erastin treatment (Fig. 3d).

Mitochondria are highly dynamic organelles with variable morphology, number and distribution within cells. Mitochondrial fusion includes the fusion of the outer and inner membranes, which is manipulated by three dynamin-related GTPases, i.e., mitofusin 1 (MFN1), MFN2, and optic atrophy 1 protein (OPA1). Mitochondrial fission is mainly controlled by dynamin-related proteins (DRPs) in eukaryotes, members of which are large self-assembling GTPases. The downregulation of the MFN1 and OPA1 genes, as well as the upregulation of the DRP1 gene (Supplementary Fig. 15) by ZnO NPs, explains the fragmented mitochondria. This result is consistent with the conclusions from TEM and MitoTracker® Deep Red FM staining. Together, these results further demonstrated that ZnO NPs-induced ferroptosis is a mitochondrial-driven cell death.

**P53 functions as a pivotal master gene in ZnO NPs-induced ferroptosis**

A pioneering study by Jiang et al. implicated that p53 sensitizes cells to ferroptosis. P53 acetylation is crucial for its activity mediating ferroptosis. Interestingly, the activation of p53 by ZnO NPs has been reported in different occasions. qRT-PCR and western blotting results showed that ZnO NPs increased p53 mRNA and protein expression, respectively (Fig. 4a, b). A reduced apoptosis rate was achieved using p53 siRNA in ZnO NPs-treated HUVECs, further illustrating that the abrogation of p53 enhanced cellular tolerance toward ZnO NPs (Fig. 4c). The induction of p53 was presumed to be associated with oxidative stress. After inhibiting p53 expression using siRNA, we found that the mRNA level of the ferroptosis biomarker PTGS2 was significantly downregulated by ZnO NPs (Fig. 4d). DCFH-DA analysis showed that p53 siRNA reduced intracellular ROS levels (Fig. 4e).

GSH depletion and lipid peroxidation are major hallmarks of ferroptotic cell death. P53 binds to the system 

---

**Fig. 2 ZnO NPs exposure disrupts iron homeostasis.** HUVECs were treated with ZnO NPs (5 or 10 μg/mL) for 24 h and total RNA was extracted for the analysis of a TFRC, b DMT1, and c FPN1 mRNA levels. d Lillie divalent iron staining. Scale bar = 20 μm. e FTH and f FTL mRNA levels. Data are shown as the mean ± S.D. from three independent experiments.

---

Zhang et al. Cell Death and Disease (2020) 11:183
Fig. 3 ZnO NPs exposure dysregulates mitochondrial dynamics. HUVECs were treated with ZnO NPs (10 μg/mL) or erastin (25 μM) for 24 h. 

a Typical TEM morphological images of ZnO NPs or erastin-treated cells. Scale bar = 1 μm. Total RNA was extracted for the analysis of (b) VDAC2 and (c) VDAC3 mRNA levels using qRT-PCR. 

d Representative MitoTracker® Deep Red FM staining (50 nM) to assess the mitochondrial morphology in HUVECs. Cells were subjected to super-resolution confocal microscopy. Scale bar = 10 μm. Data are shown as the mean ± S.D. of three independent experiments.

Zhang et al. Cell Death and Disease (2020) 11:183
p53 siRNA abrogated this effect (Fig. 4g). The protein expression levels of SLC7A11 and SAT1 correspond to their mRNA levels (Supplementary Fig. 16). SAT1 siRNA treatment inhibited ALOX15 and PTGS2 mRNA levels, suggesting the inhibition of ferroptosis, whereas no increase was observed in the levels of the other two lipoxygenases, arachidonate 5-lipoxygenase (ALOX5) and arachidonate 12-lipoxygenase (ALOX12) (Supplementary Fig. 17). Notably, although accumulating evidence supports the activity of p53 in the regulation of ferroptosis, p53 alone is incapable of inducing ferroptosis37.

Particle remnants and Zn2+ ions both contribute to ZnO NPs-induced ferroptosis

In addition to reported variations in cytotoxicity, there is no consensus on the underlying mechanisms that drive the toxicity of ZnO NPs, i.e., the ZnO particles per se, the released Zn2+ or their combination. Zn2+ is released from the surface of ZnO NPs when they are suspended in aqueous state, both in medium and organelles with low pH38.

To more precisely follow particle processing behavior in cells, fluorescent-labeled F-ZnO NPs were generated by grafting the particle surface with (3-aminopropyl)triethoxysilane (APTS), followed by the addition of the amine-reactive dye fluorescein isothiocyanate (FITC)39. Green fluorescent spots indicated the uptake of F-ZnO NPs by cells (Fig. 5a). To test whether ZnO NPs-induced ferroptosis is associated with Zn2+ release inside cells, we performed cellular staining with Zn2+-specific fluorescent dye N-(6-methoxy-8-quinolyl)-p-toluenesulfonamide (TSQ)40. Compared with the low intensity staining of untreated HUVECs, F-ZnO NPs-treated cells showed a generalized increase in blue fluorescence with prominent staining of the cellular membrane that was stained by Dil, suggesting that Zn2+ derived from the particle remnants concentrates in the cells (Fig. 5b). Next, we discuss the subcellular localization of F-ZnO NPs in cells41. After incubation with F-ZnO NPs for 24 h, F-ZnO NPs were colocalized with lysosomal fluorescent spots, resulted in a composite orange fluorescence profile (Fig. 5c). In addition, the overlap of fluorescent signals from TSQ and Lyso Tracker Red suggested that Zn2+ derived from the particles concentrates in the lysosomal compartment (Fig. 5d).

We then attempted to mimic the intracellular behavior of ZnO NPs by investigating Zn2+ release in PBS at pH 7.4 and artificial lysosomal fluid (ALF) at pH 4.5. As presented in Fig. 5e, the overall amount of released Zn2+ present in PBS solution was considerably lower than corresponding amount measured in ALF. At the highest concentration of ZnO NPs exposure (15 µg/mL), Zn2+ concentrations corresponding to the dissolution of the NPs were 54% (in ALF) and 11% (in PBS). This result implied the massive degradation of ZnO NPs in lysosomes. For comparative purposes, the concentration of Zn2+ inside the cell was also evaluated. The measurement resulted in an average Zn2+ concentration per cell after 24 h of ZnO NPs incubation. The
supernatant zinc concentration represented dissolved $\text{Zn}^{2+}$, while the total zinc (including particle remnants and dissolved $\text{Zn}^{2+}$) was achieved by acidification (Fig. 5f). From the data of the dissolved $\text{Zn}^{2+}$ to total $\text{Zn}^{2+}$ ratio, we conclude that the majority (~60%) of ZnO NPs rapidly degraded into $\text{Zn}^{2+}$ after entering the cells (presumably in the acidic lysosomal compartment), which is similar to that found in the ALF simulation. The dissolution of ZnO NPs into $\text{Zn}^{2+}$ is dependent on the properties of the particles as well as the media42.

Zinc is mostly bound to proteins or sequestered in lysosomes; however, no $\text{Zn}^{2+}$ signal in the control group indicates that intrinsic zinc does not affect this measurement (Fig. 5f). To rule out a surface effect of ZnO NPs, i.e., the formation of ZnO NPs agglomerates and interaction with the cell membrane, we compared the uptake of particle (ZnO NPs) and dissolved $\text{Zn}^{2+}$ (ZnCl$_2$), at concentrations normalized to $\text{Zn}^{2+}$ inside the cells, compared with $10 \mu$g/mL ZnO NPs for 24 h. Lillie divalent iron staining analysis was performed. Scale bar = 20 $\mu$m.

![Fig. 5 Particle remnants and $\text{Zn}^{2+}$ ions both contribute to ZnO NPs-induced ferroptosis.](image) Super-resolution confocal microscopy was used to study the uptake of F-ZnO NPs and the cellular distribution of $\text{Zn}^{2+}$. HUVECs were treated with F-ZnO NPs at concentrations of 10 $\mu$g/mL for 24 h. After permeabilization and fixation, cells were stained with a the cellular membrane marker DiI (20 $\mu$M), b DiI (20 $\mu$M) and $\text{Zn}^{2+}$-specific fluorescent dye TSQ (30 $\mu$M), c Lyso Tracker Red (1 $\mu$M), or d Lyso Tracker Red (1 $\mu$M) and TSQ (30 $\mu$M). Then, cells were subjected to super-resolution confocal microscopy. Scale bar = 10 $\mu$m. e ZnO NPs were exposed to PBS at pH 7.4 and artificial lysosomal fluid (ALF) at pH 4.5 for 24 h and the free $\text{Zn}^{2+}$ content was analyzed by AAS. f HUVECs were exposed to ZnO NPs for 24 h, and the dissolved $\text{Zn}^{2+}$ and total $\text{Zn}^{2+}$ contents were analyzed by AAS. $\text{Zn}^{2+}$ content is expressed as pg/cell. g HUVECs were exposed to ZnO NPs or ZnCl$_2$ for 24 h and the dissolved $\text{Zn}^{2+}$ content was analyzed by AAS. $\text{Zn}^{2+}$ content is expressed as pg/cell. The results are presented as the mean ± S.D. of four replicates. h HUVECs were exposed to $10 \mu$g/mL ZnO NPs or $31.9 \mu$g/mL ZnCl$_2$ (stoichiometric equivalent of $\text{Zn}^{2+}$ inside the cells, compared with $10 \mu$g/mL ZnO NPs) for 24 h. Lillie divalent iron staining analysis was performed. Scale bar = 20 $\mu$m.
shows that Zn\(^{2+}\) induces comparable staining when compared with stoichiometric equivalent ZnO NPs (inside the cells), which confirms that Zn\(^{2+}\) induces ferroptosis by direct ZnCl\(_2\) exposure. To further nail the effect of dissolved Zn\(^{2+}\) on ferroptosis, a set of parallel experiments were conducted by direct exposure of cells to ZnCl\(_2\) (equal amount of Zn\(^{2+}\) in the cells) and comparable results were obtained, compared with ZnO NPs (Supplementary Fig. 18).

The amount of Zn\(^{2+}\) leached from the ZnO NPs then taken up by cells seems to be insignificant, as the majority of dissolved Zn\(^{2+}\) was found in the acidic compartment (Fig. 5e) and the internalization of zinc was weakened for Zn\(^{2+}\) form (Fig. 5g). Therefore, in the case of ZnO NPs exposure, dissolved Zn\(^{2+}\) plays the dominant role in ferroptosis. The dynamic equilibrium of zinc dissolution is not discussed here, therefore, an independent study demonstrated that the dissolution of ZnO NPs reached 80% of the maximum dissolved Zn\(^{2+}\) within 31 h.\(^{41}\) Together, it is safely concluded that the ZnO NPs-induced ferroptosis is primarily due to the enhancement of the intracellular concentration of Zn\(^{2+}\).

**Ferroptosis is a general form of cell death induced by NMs**

We next ask whether only ZnO NPs, or only ion-leaking NPs, has the ability of triggering ferroptosis. Therefore, we performed an intracellular ferrous iron staining analysis with 21 different NMs. Most of the NMs used are 0-dimensional, but there are also 1-dimensional carbon nanotubes and 2-dimensional graphene oxide (Supplementary Table 2). The primary size of these NMs are between 5 and 200 nm. These NMs are positively or negatively charged with good dispersities, both in PBS and in RPMI1640 medium. Most of NMs have a certain degree of influence on the accumulation of iron in HUVECs, suggesting a specific proferroptotic effect of NMs (Fig. 6), and related quantification was provided in Supplementary Fig. 19. This effect cannot be attributed to metal ions released from the NPs. Although a similar downstream cell-death phenotype was found, ferroptosis inducers may activate different signal pathway; for example, erastin modulates VDAC2/3\(^{22}\) and system X\(_{-}\)^{−4} to trigger ferroptosis, while Ras-selective lethal small molecule 3 (RSL 3) does not affect these factors.\(^{44}\) As shown, most of NMs upregulated ferroptotic gene expressions (Supplementary Fig. 20), however, whether these NMs with different characteristics (composition, size, shape, and surface charge) share the same ferroptotic mechanism as ZnO NPs is currently unknown. To prove the universal principle that applies in ZnO NPs-induced cell death, multiple cell lines with different resources were tested. The results resemble those found with HUVECs in appearance (Supplementary Fig. 21). Nevertheless, the nature of the death signal responsible due to ZnO NPs exposure (along with other NMs) has not been completely defined. Further investigation would be beneficial for improving the understanding of the mechanisms governing NMs-induced cell death.

**Discussion**

As usage of NMs rapidly grows, it is urgent and important to assess their safety. Previous in vitro and in vivo studies demonstrated the association of ZnO NPs exposure with various cell-death pathways; however, whether ZnO NPs, along with other “iron free” NMs induce ferroptosis has not been reported. In the present work, we identified that ferroptosis is a general cell death caused by NMs. The occurrence of ferroptosis is evidenced biologically, genetically, and morphologically.

The most important finding in the current study is, unlike previous findings, our data support that “iron free” NMs trigger ferroptosis. Thus, we attempt to address its fundamental principle. Considering the different compositions and properties (size, shape, and zeta potential) of NMs, the common mechanism that leads to ferroptosis is excess ROS. After their internalization, NMs favorably mobilize to mitochondria and dysregulate the mitochondrial antioxidant defense system. Alternatively, the proinflammatory effect is an intrinsic nature of NMs that may cause ROS. These two mechanisms are applied to the majority of NMs regardless of their composition or other characteristics. Although gold and silver-constituent NMs are relatively chemically inert, their exposures to cells are also linked with the promotion of ROS. Another vital finding in the current study is that ZnO NPs-induced dysregulation of iron homeostasis. Elements have redox properties, such as iron, may catalyze the production of ROS. By taking advantage of the Fenton reaction and Haber-Weiss reaction, iron-oxide-based NMs were designed and synthesized for anticancer therapy.\(^{45,46}\) In fact, numerous examples of damage to cells, in which iron are implicated. However, “iron free” ZnO NPs do not provide iron essentially, the source of iron under physiological condition, where iron availability is relative low, need to be discussed. Lysosomes (the main NMs-targeting organelle) and mitochondria may release iron from the LIP. Although ZnO NPs exhibited rather complicated regulation on iron uptake, storage and export related gene expressions, however, an overall consequence of ZnO NPs exposure is iron accumulation, which implied that the iron-dysregulation mechanism plays an important role in ZnO NPs-induced ROS formation. Alternatively, ROS-mediated mitochondrial damage may defect heme and iron–sulfur cluster-containing proteins synthesis, and in turn accumulates “free” iron in mitochondria. Therefore, ROS formation and the dysregulation of iron homeostasis is an interdependent event. Dixon and Stockwell summarized how iron and ROS contribute to a variety of
Fig. 6 Nanomaterials cause intracellular Fe^{2+} elevation in HUVECs. HUVECs were exposed to 10 μg/ml of listed nanomaterials or 25 μM erastin for 24 h, and subjected to Lillie divalent iron staining. Red circled images indicated insignificant staining. Scale bar = 20 μm.
cell-death pathways, including ferroptosis. Of note, we have no intention to attribute NMs-induced ferroptosis solely to ROS, individual investigations of different NMs are encouraged.

The third interesting finding in the current study is that ZnO NPs-induced dysregulation of iron homeostasis partially due to dissolved Zn\(^{2+}\). Although Zn\(^{2+}\) is an inert cation and does not undergo a redox reaction, Zn\(^{2+}\) overload is closely related to ROS and subsequently mitochondrial injuries. The aberrant homeostasis of transition metal ions, e.g., Fe\(^{2+}/Fe^{3+}\), Zn\(^{2+}\), and Ca\(^{2+}\), plays important roles in the pathogenesis of various diseases. For instance, a recent study has highlighted the interaction of Zn\(^{2+}\) homeostasis and ROS signaling suggesting their interdependence. Mitochondria contain dynamic pools of these metal ions that are incorporated into corresponding metalloproteins. Thus, Zn\(^{2+}\) overload-triggered mitochondrial injuries may exaggerate the dysregulation of dynamic metal pools (including the LIP), resulting in the elevation of intracellular iron and ultimately ferroptosis. Interestingly, both ZnO NPs and Zn\(^{2+}\) were reported to disrupt intracellular Ca\(^{2+}\) homeostasis, which activates Ca\(^{2+}\)-dependent pro-death signaling. Our current results facilitate the understanding of the cell-death mechanism involved in the disruption of metal ion homeostasis.

A recent review summarized the effect of p53 on the regulation of ferroptosis network. Specifically, the pro-death function of p53 in ferroptosis was mutually found in previous and current study, includes the inhibition of SLC7A11 expression and the promotion of SAT1 expression. On the contrary, the pro-survival function of p53 in ferroptosis have been also reported, suggested the bipolar regulation of p53 on cell death. Interestingly, there are several reports in which zinc can either block or accelerate apoptosis, due to different experimental settings. Under mild ROS conditions, p53 stimulates the expression of antioxidant genes to restore oxidative homeostasis, whilst extreme ROS level initiate apoptosis through p53. Notably, the activation of p53 may in turn induce ROS production by regulating certain genes. ZnO NPs-induced signaling that associated with p53 has been reviewed. At last but not least, the current study, for the first time, demonstrated that ZnO NPs-induced ferroptosis is p53-dependent; however, whether p53 has other functions in ZnO-induced ferroptosis is unknown. For instance, other work reported that acute exposure of eukaryotes to Zn\(^{2+}\) decreased intracellular iron content; however, no information regarding to p53 regulation and ferroptosis has been released. In addition, it is commonly accepted that p53 involved in multiple line of cell death, including apoptosis, necrosis and autophagy, however, the activities of p53 in ZnO NPs (or Zn\(^{2+}\))-induced cell death are indistinct; since several cell death share ROS/p53 axis collectively, whether these are pivotal molecules that manipulate the cross talk of these cell death is not currently understood.

![Fig. 7 Proposed mechanism of ZnO NPs-induced ferroptosis.](image-url)

Ferroptosis is initiated via various signal pathways, such as Fe\(^{2+}\) accumulation, glutathione depletion and lipid peroxidation. The ZnO NPs can be endocytosed into lysosomal compartments where ZnO dissolves and releases zinc ions into the cytoplasm. ZnO NPs and zinc ions in the cytoplasm can activate p53, which may repress the transcription of SLC7A11, a component of the cystine/glutamate antporter and glutathione depletion, and trigger SAT1 gene expression is enhanced in the presence of activated p53. Similarly, ZnO NPs and zinc ions in the cytoplasm can also impair organelles such as mitochondria and disrupting iron metabolism, and subsequent ferroptosis can occur by over-accumulation of lipid ROS.
In summary, the current study demonstrated that ZnO NPs-induced cell death coincides with the definition of ferroptosis. We conclude that HUVECs death induced by ZnO NPs includes ferroptosis, in addition to apoptosis, autophagy, and necroptosis. ZnO NPs cause ferroptosis by disrupting iron metabolism (iron overload), mitochondrial dynamics (increased mitochondrial fission) and redox homeostasis (GSH depletion and lipid peroxidation generation), which appears to be a p53-driven process (mechanism summarized in Fig. 7). This is the first comprehensive investigation on the role of “iron free” NMs in ferroptotic cell death, which emphasizes the importance of understanding NMs-induced cell death.

Acknowledgements
This work is supported by The National Key Research and Development Program of China (2016YFO0400200), National Natural Science Foundation of China (21627204, 21575118 and 20171881), Fundamental Research Funds for the Central Universities (XDJK2017J001 and Basic Science and Frontier Technology Research Project of Chongqing (cstc2015jcyjA0939).

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information
accompanies this paper at (https://doi.org/10.1038/s41419-020-2384-5).

Received: 11 November 2019 Revised: 24 February 2020 Accepted: 25 February 2020

Published online: 13 March 2020

References
1. Zhao, F. et al. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 7, 1322–1337 (2011).
2. Nél, A., Xia, T., Madler, L. & Li, N. Toxic potential of materials at the nanolevel. Science 311, 622–627 (2006).
3. Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486–541 (2018).
4. Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072 (2012).
5. Dixon, S. J. & Stockwell, B. R. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 10, 9–17 (2014).
6. Xie, Y. et al. Ferroptosis: process and function. Cell Death Differ. 23, 369–379 (2016).
7. Shen, Z. et al. Emerging strategies of cancer therapy based on ferroptosis. Adv. Mater. 30, e1704007 (2018).
8. Kim, S. E. et al. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nat. Nanotechnol. 11, 977–985 (2016).
9. Ou, W. et al. Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma. Free Radic. Biol. Med. 112, 597–607 (2017).
10. Szewcz, M. et al. Small variations in nanoparticle structure dictate differential cellular stress responses and mode of cell death. Nanotoxicology 13, 761–782 (2019).
11. Liu, J. et al. The toxicology of ion-shedding zinc oxide nanoparticles. Crit. Rev. Toxicol. 46, 348–384 (2016).
12. Giga, A. R., Skoglund, S., Wallinder, I. O., Fadeel, B. & Kafsson, H. L. Sizen-dependent cytotoxicity of silver nanoparticles in human lung cells: the role of cellular uptake, agglomeration and Ag release. Part. Fibre Toxicol. 11, 11 (2014).
13. Samet, J. M., Dominici, F., Curriero, C. F., Couros, I. & Zeger, S. L. Fine particulate air pollution and mortality in 20 U.S. cities, 1987–1994. N. Engl. J. Med. 343, 1742–1749 (2000).
14. Gojova, A. et al. Induction of inflammation in vascular endothelial cells by metal oxide nanoparticles: effect of particle composition. Environ. Health Perspect. 115, 403–409 (2007).
15. Akhtar, M. J. et al. Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen species. Int. J. Nanomed. 7, 845–857 (2012).
16. Johnson, B. M. et al. Acute exposure to ZnO nanoparticles induces autophagic immune cell death. Nanotoxicology 9, 737–748 (2015).
17. García-Chávez, L. et al. Nano-ZnO leads to tubulin macrotubule assembly and actin bundling, triggering cytoskeletal catastrophe and cell necrosis. Nanoscale 8, 10963–10973 (2016).
18. Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014).
19. Doli, S. et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13, 91–98 (2017).
20. Kagan, V. E. et al. Oxidized arachidonic and adrenic PE navigate cells to ferroptosis. Nat. Chem. Biol. 13, 81–90 (2017).
21. Donovan, A. et al. The iron exporter ferroportinSlc40a1 is essential for iron homeostasis. Cell Metab. 1, 191–200 (2005).
22. Drakesmith, H., Nemeth, E. & Ganz, T. Ironing out ferroportin. Cell Metab. 22, 777–787 (2015).
23. Mano, S. et al. Heme controls ferroportin (FPN1) transcription involving Bach1, Nr2f2 and a MARE/ARE sequence motif at position -7007 of the FPN1 promoter. Haematologica 95, 1261–1268 (2010).
24. Nemeth, E. et al. Heparin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090–2093 (2004).
25. Fleming, R. E. & Ponka, P. Iron overload in human disease. N. Engl. J. Med. 366, 348–359 (2012).
26. Eaton, J. W. & Qian, M. Molecular bases of cellular iron toxicity. Free Radic. Biol. Med. 32, 833–840 (2002).
27. Yagoda, N. et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447, 864–868 (2007).
28. Dolma, S., Lessnick, S. L., Hahn, W. C. & Stockwell, B. R. Identification of genetotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285–296 (2003).
29. Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57–62 (2015).
30. Wang, S. J. et al. Acetylation is crucial for p53-mediated ferroptosis and tumor suppression. Cell Rep. 17, 366–373 (2016).
31. Kuma, A., Najafzadeh, M., Jacob, B. K., Dhawan, A. & Anderson, D. Zinc oxide nanoparticles affect the expression of p53, Ras p21 and JNKs: an ex vivo/in vitro exposure study in respiratory disease patients. Mutagenesis 26, 237–245 (2011).
32. Ng, K. W. et al. The role of the tumor suppressor p53 pathway in the cellular DNA damage response to zinc oxide nanoparticles. Biomaterials 32, 8218–8225 (2011).
33. Roy, R. et al. Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition. Toxicol. Lett. 227, 29–40 (2014).
34. Seshawati, M. I., Tay, C. Y. & Leong, D. T. Effect of zinc oxide nanomaterials-induced oxidative stress on the p53 pathway. Biomaterials 34, 10133–10142 (2013).
35. Stockwell, B. R. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273–285 (2017).
36. Ou, Y., Wang, S. J., Li, D., Chu, B. & Gu, W. Activation of S1AT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc. Natl Acad. Sci. USA 113, E6906–E6912 (2016).
37. Murphy, M. E. Ironing out how p53 regulates ferroptosis. Proc. Natl Acad. Sci. USA 113, 12350–12352 (2016).
38. Zhu, X., Wang, J., Zhang, X., Chang, Y. & Chen, Y. The impact of ZnO nanoparticle aggregates on the embryonic development of zebrafish (Danio rerio). Nanotechnology 20, 195103 (2009).
39. Moos, P. J. et al. ZnO particulate matter requires cell contact for toxicity in human colon cancer cells. Chem. Res. Toxicol. 23, 733–739 (2010).
40. Meeusen, J. W., Tomasiewicz, H., Nowakowski, A. & Petering, D. H. TSQ (6-methoxy-8-p-toluenesulfonamido-quinoline), a common fluorescent sensor for cellular zinc, images zinc proteins. Inorg. Chem. 50, 7563–7573 (2011).
41. Kao, Y. Y., Chen, Y. C., Cheng, T. J., Chiung, Y. M. & Lu, P. S. Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity. Toxicol. Sci. 125, 462–472 (2012).
42. Pasquet, J. et al. The contribution of zinc ions to the antimicrobial activity of zinc oxide. Colloid Surf. A 457, 263–274 (2014).
43. Xia, T. et al. Comparison of the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolution and oxidative stress properties. ACS Nano. 2, 2121–2134 (2008).
44. Yang, W. S. & Stockwell, B. R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 15, 234–245 (2008).
45. Shen, Z. et al. Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors. ACS Nano. 12, 11355–11365 (2018).
46. Zhou, Z. et al. Activatable singlet oxygen generation from lipid hydroperoxide nanoparticles for cancer therapy. Angew. Chem. Int. Ed. Engl. 56, 6492–6496 (2017).
47. Sadli, N., Barrow, C. J., McGee, S. & Suphioglu, C. Effect of DHA and coenzymeQ10 against Abeta- and zinc-induced mitochondrial dysfunction in human neuronal cells. Cell Physiol. Biochem. 32, 243–252 (2013).
48. Gazaryan, I. G., Istrinisvaya, I. P., Kristal, B. S. & Brown, A. M. Zinc irreversibly damages major enzymes of energy production and antioxidant defense prior to mitochondrial permeability transition. J. Biol. Chem. 282, 24373–24380 (2007).
49. Slepchenko, K. G., Lu, Q. & Li, Y. V. Crosstalk between increased intracellular zinc (Zn(2+)) and accumulation of reactive oxygen species in chemical ischemia. Am. J. Physiol. Cell Physiol. 313, C448–C459 (2017).
50. Finney, L. A. & O’Halloran, T. V. Transition-metal speciation in the cell. Insights from the chemistry of metal ion receptors. Science 300, 931–936 (2003).
51. Huang, C. C., Aroostam, R. S., Chen, D. R. & Huang, Y. W. Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles. Toxicol. Vitr. 24, 45–55 (2010).
52. Guo, D., Du, Y., Wu, Q., Jiang, W. & Bi, H. Disrupted calcium homeostasis is involved in elevated zinc ion-induced photoreceptor cell death. Arch Biochem Biophys. 560, 44–51 (2014).
53. Vander Jagt, T. A., Connor, J. A., Weiss, J. H. & Shuttleworth, C. W. Intracellular Zn(2+) increases contribute to the progression of excitotoxic Ca(2+) increases in apical dendrites of CA1 pyramidal neurons. Neuroscience 159, 104–114 (2009).
54. Kang, R., Kroemer, G. & Tang, D. The tumor suppressor protein p53 and the ferroptosis network. Free Radic. Biol. Med. 133, 162–168 (2019).
55. Ostrokhovitch, E. A. & Cherian, M. G. Differential regulation of signal transduction pathways in wild type and mutated p53 breast cancer epithelial cells by copper and zinc. Arch. Biochem. Biophys. 423, 351–361 (2004).
56. Pagani, M. A., Casamayor, A., Serino, R., Atrian, S. & Arino, J. Disruption of iron homeostasis in Saccharomyces cerevisiae by high zinc levels: a genome-wide study. Mol. Microbiol. 65, 521–537 (2007).